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Depo-Provera 
Does this Contraceptive Choice Support 
the Health and Well-Being of 
Adolescents and Young Women'? 
Depo-Provera approuvk par Santk 
Canada comme contracqtifen 1997 
est une mkthode contraceptive trks 
controverskequi est utiliskepar lesjeunes 
femmes et les adolescentes. Deux 
kvknements rkcents remettent en ques- 
tion ce choix de contraceptzyrt cause des 
efets ssur h santkdes jeunesfilles et leur 
bien-&re. 
Two recent events challenge com- 
mon beliefs held in the sexual and 
reproductive health community con- 
cerning reproductive choice and 
health and wellness for adolescents 
and young women. 
The firstwas ascientificforum, CO- 
sponsored by the Society for Men- 
strual Cycle Research (SMCR), ti- 
tled "The Menstrual Cycle is a Vital 
Sign" held at the New York Academy 
of Sciences on September 21, 2004. 
Elizabeth Kissling, Ph.D., a commu- 
nications professor at Eastern Wash- 
ington University, board director of 
SMCRand current chair of the board 
for Planned Parenthood of the In- 
land Northwest, began the session 
with an overview of how menstrua- 
tion is represented in the media. She 
was followed by several leading medi- 
cal experts who presented research- 
based evidence to demonstrate why 
the menstrual cycle is a critical indi- 
cator of women's overall health. 
The main point? When a woman's 
menstrual cycle does not function 
within normal parameters, her gen- 
eral health is at risk because multiple 
body systems are impacted by men- 
strual dysfunction. At this forum, 
Dr. Paula Hillard, director of wom- 
en's health for the College of Medi- 
cine at the University of Cincinnati, 
suggested that menstrual disorders in 
teenagers should be evaluated for fac- 
tors that may be interfering with 
normal maturation of the reproduc- 
tivesystemprior to management with 
medications such as oral contracep- 
tives. 
The second event was a "black 
box" warning issued November 17, 
2004 by the U.S. Food and Drug 
Administration (FDA) concerning 
Depo-Provera Contraceptive Injec- 
tion. Depo-Provera, given by injec- 
tion once every three months, pre- 
vents pregnancy by interfering with 
normal maturation of eggs in the 
ovaries, altering cervical mucus and 
suppressing the normal production 
of estrogen, progesterone and testo- 
sterone. 
The warning? Long-term use (de- 
fined as two years or more) of Depo- 
Provera is associated with significant 
bone mineral density loss that may 
not be reversible. ~ h e d r u ~ ,  approved 
for use in Canada as a contraceptive 
in 1997, has doubled in use between 
1999 and 2003. In 2003 almost 
625,000 prescriptions were written 
for Depo-Provera (Picard). Many, if 
not the majority, of them were for 
teenagers and women in their 20s. 
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How does the sexual and repro- 
ductive health community analyze 
the significance of these two events? 
Does the research showing how fe- 
male health is predicated on a fully 
functioning menstrual cycle raise 
questions we would rather not exam- 
ine? When, if ever, should our com- 
mitment to reproductive choice de- 
fer to the health and wellness of the 
adolescents and young women we 
serve? 
The menstrual cycle as a vital sign 
and the use of Depo-Provera as a 
contraceptive constitute two ends of 
a continuum. At one end is normal 
menstruation, a critical indicator of 
women's overall health. At the other 
is complete menstrual suppression, 
or dysfunction, induced by a drug 
that shuts down normal reproduc- 
tive endocrine function. Along the 
continuum is a range of menstrual 
disorders caused by hormonal imbal- 
ances due possibly to diet, exercise, 
life style, stress, inherent factors or 
those induced by other hormonal 
contraceptives such as the pill or 
patch. 
This continuum is avalid topic for 
discussion because of the often ig- 
nored truth that birth control drugs 
were and are developed to purposely 
disrupt a healthy functioning sys- 
tem. Hormonal contraception works 
by disrupting the menstrual cycle to 
induce temporary infertility. We ac- 
cept this dysfunction, and the side 
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effects that can ensue, for the major pressure. Other benefits include treatmentforosteoporosisis pre- 
benefit ofpregnancyprevention. But 
what if there comes a point at which 
the costs to women's healthoutweigh 
the benefits? 
It is instructive to first understand 
what health benefits accrue to women 
who ovulate and menstruate regu- 
larly. In a letter to Dr. Susan Rako, 
that serves as an introduction to 
Rako's book No More Periods?, 
pheromone production to influence 
sexual attraction to immunologically 
suitable partners and strong immune 
function to fight off infection (think 
STIs) (Rako). 
T. S. Wiley, in Sex, Lies andMeno- 
pause, exhaustively corroborates how 
"in the hormonal interplay of pro- 
gesterone and estrogen during the 
menstrual cycle, nature gives us the 
vention and one approach to 
prevention is by optimizing bone 
mass, we need to make every 
effort to maximize this process. 
(354) 
Providing Depo-Provera to young 
women who should be building, not 
losing bone mass undermines this 
strategy. 
As a contraceptive choice for teenagers and young women, 
Depo-Provera provides them the o p p o ~ u n i t y  t o  experience loss 
of libido, vaginal dryness, unmanageabfe weight gain, depression, 
bone Ioss and other unpleasant outcomes in exchange 
for pregnancy prevention. 
Winnifred B. Cutler, president and 
founder of the Athena Institute for 
Women's Health in Pennsylvania, 
provides this summation: 
All sex hormones affect physi- 
ological systems, including car- 
diovascular health, bone me- 
tabolism, cognitive functions, 
sexual response, and sexual at- 
tractiveness. The fertile men- 
strual cycle serves more than just 
the next generation. A fertile 
pattern of hormonal secretions 
promotes general health and 
well-being. This coordinated 
pattern is well illustrated in a 
graceful sequence of fluctuating 
ebbs and flows of blood-borne 
hormones secreted by the ovary: 
estrogens, progesterone, and 
testosterone. And with this 
rhythmic cyclic alteration in sex 
hormones come consequent al- 
terations in psychodynamic 
events, such as dreaming, en- 
ergy, and cognition. (13) 
The book explores the research on 
the health impacts of menstruation, 
documenting the benefits to wom- 
en's health. The heart protective ben- 
efits of normal periods include the 
depletion ofexcessive stored iron and 
a regulatory mechanism for blood 
prescription for health" (29). The 
author demonstrates how rhythmic 
cycling of these two hormones pro- 
tects young and pre-menopausal 
women from cancer, heart disease, 
Alzheimer's, and osteoporosis. 
If regular ovulatory menstruation 
plays such an important part in main- 
taining overall health then what are 
the potential repercussions of a drug 
like Depo-Provera? First, and per- 
haps most critically, there is signifi- 
cant bone loss that may not be com- 
pletely reversible. A 1996 study ex- 
amined bone density among adoles- 
cents receiving different forms of 
hormonal contraception along with 
that of control subjects. Results 
showed that "after two years, bone 
density increased a total of 9.3% in 
Norplant users and 9.5% in control 
subjects but decreased a total of3.1% 
in Depo-Provera users" (Cromer et 
al. 671). This translates to a net bone 
loss of about 12 per cent over two 
years in the Depo-Provera users when 
compared to the bone density gains 
measured in the non-Depo subjects. 
In a 2003 paper, Barbara Cromer 
writes: 
There remains substantial con- 
cern about the potential com- 
promise of peak bone mass in 
very young women. As the best 
Other acknowledged and poten- 
tial side effects ofDepo-Provera range 
from the annoying to the alarming. 
Health Canada has received 480 
reports of suspected adverse reactions 
in women tahng Depo-Provera since 
its approval in 1997. These reactions 
included vaginal and uterine 
hemorrhage, excessive menstrual 
bleeding, facial paralysis, memory 
loss, ectopic pregnancies, suicidal ten- 
dencies, depression, nervousness, 
anxiety and panic reactions (Kirkey 
A14). 
In No More Periodr?Rako provides 
a long list of other adverse reactions. 
Although this drug effectively (99.7 
per cent) prevents pregnancy, taking 
it can be decidedly unpleasant to say 
the least. 
Headaches are the most common 
side effect. Abdominal distress in- 
cluding pain, nausea, bloating and 
constipation are common because 
Depo-Provera loosens the tone of the 
muscles in the gastrointestinal tract. 
Though complete menstrual sup- 
pression occurs in many women, 
bleeding and spotting can precede 
amenorrhea. Women can experience 
no bleeding, spotting, unpredictable 
bleeding, or nonstop bleeding. 
One acknowledged outcome of 
Depo-Provera use is the time delay 
(three to 18 months or longer) after 
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the last shot for a full return to fertil- 
ity. This recovery time can be, for 
some women, fraught with distress- 
- 
ing health problems for which no 
apparent treatment protocol exists. 
Weight gain is extremely common 
and more extreme in teenagers than 
adult women. Many women discon- 
tinue the drug for this reason. 
The depressive effects of Depo- 
Provera are well known. Severe de- 
pression, anxiety, and paranoia have 
all been reported. Some women ex- 
perience symptoms while on it, oth- 
ers experience depression after stop- 
ping the drug. 
Hot flashes, vaginal dryness, and 
other menopausal symptoms experi- 
enced by some women are directly 
due to the "bottomed-out levels of 
estrogen and testosterone" (Rako 
1 10) that are also responsible for loss 
of bone density. Loss of desire for sex 
and loss of sexual sensitivity are also 
subsequent to hormonal depletion. 
Herein lays the irony of Depo- 
Provera use by young women. The 
drug induces the hormonal profile of 
a menopausal woman and with it the 
potential to experience the full con- 
stellation ofsymptoms (once thought 
to be all in women's heads) that can 
so diminish the quality of life for 
women in mid-life and beyond. 
As a contraceptive choice for teen- 
agers and young women, Depo- 
Provera provides them the opportu- 
nity to experience loss of libido, vagi- 
nal dryness, unmanageable weight 
gain, depression, bone loss and other 
unpleasant outcomes in exchange for 
pregnancy prevention. 
These negative side-effects cause 
many women to stop using the drug, 
but others tolerate them, often not 
aware their symptoms are related to 
their choice of contraceptive. The 
other irony? Women who tolerate 
Depo-Provera best are most likely to 
take it long-term and, therefore, are 
most at risk for significant and po- 
tentially irreversible bone loss. 
There may well be some appropri- 
ate reasons for using Depo-Provera, 
such as severe endometriosis, proven 
contraindication for estrogen-based 
contraceptives or exceptional life cir- 
cumstances. Butwhat aresome ofthe 
main reasons its use by NorthAmeri- 
can adolescents and young women 
has skyrocketed in the last few years? 
It is convenient: you don't have to 
remember to take a pill every day. It 
will suppress menstruation: no more 
pesky periods. It is discreet: your par- 
ents won't find out you're on birth 
control. Good reasons? Or just suc- 
cessful marketing messages? 
Considering the many evident and 
potential ill effects of using this drug, 
it may be time to reassess the suitabil- 
ity of Depo-Provera as a first choice 
contraceptive by teenagers or a con- 
venient, discreet method of choice 
for young women. 
In June 2005, the SMCRwill host 
its 16th conference: "Menstruation: 
The Fifth Vital Sign." If the medical 
profession adopts the society's posi- 
tion that the menstrual cycle is a vital 
sign for women, the sexual and re- 
productive health community may 
be compelled to rethinkhow far along 
the continuum we are prepared to go 
to prevent unintended pregnancy. 
Sexual health care providers and 
educators must surely consider them- 
selves to be stewards of young wom- 
en's health. When our commitment 
to reproductive choice takes prec- 
edence over the general health and 
well-being of the young women we 
serve, then hard questions must be 
asked. 
If Depo-Provera has such capacity 
to harm women's current and future 
health andwell-being, and ifwe must 
now acknowledge that using the drug 
for more than two years is not advis- 
able, then the first question becomes: 
When, if ever, should young women 
choose Depo-Provera? 
Laura Wershler is a sexual and repro- 
ductive healthadvocateandwriter with 
a special interest in holistic reproduc- 
tive health care. Currently she is re- 
searching the use of bio-identical hor- 
mone replacement. Laura hasa lengthy 
volunteer histoy with Planned Par- 
enthood organizations, including ten 
yearson the boardofdirectorsofPlanned 
ParenthoodFederation ofcanada. She 
now works as the Executive Director of 
Planned Parenthood Alberta in 
Calgaty. 
'Seehttp://MenstrualCycleVital 
Sign.com, full proceedings of web 
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